Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of Pharvaris stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the sale, the chief executive officer directly owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Berndt Modig also recently made the following trade(s):
- On Monday, June 15th, Berndt Modig sold 2,291 shares of Pharvaris stock. The shares were sold at an average price of $31.07, for a total transaction of $71,181.37.
Pharvaris Price Performance
Shares of Pharvaris stock opened at $36.10 on Wednesday. The company has a 50-day moving average of $33.88 and a 200 day moving average of $30.23. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of -11.84 and a beta of -2.31. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $36.93.
Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, equities analysts anticipate that Pharvaris N.V. will post -3.15 EPS for the current year.
Analysts Set New Price Targets
Several brokerages have issued reports on PHVS. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a report on Friday, July 17th. Royal Bank Of Canada lifted their price objective on Pharvaris from $51.00 to $52.00 and gave the stock an "outperform" rating in a report on Thursday, August 13th. HSBC raised Pharvaris to an "overweight" rating in a research report on Thursday, August 13th. Citizens Jmp raised their price target on shares of Pharvaris from $74.00 to $75.00 and gave the company a "market outperform" rating in a report on Thursday, August 13th. Finally, UBS Group set a $74.00 price objective on shares of Pharvaris in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $51.08.
Get Our Latest Stock Analysis on PHVS
Key Headlines Impacting Pharvaris
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: HC Wainwright maintained a Buy rating on Pharvaris. Its projections still anticipate a significant improvement in profitability over time, including positive earnings of $3.09 per share in fiscal 2029. HC Wainwright Predicts Pharvaris' Q4 Earnings
- Neutral Sentiment: HC Wainwright issued estimates for Pharvaris’ upcoming quarters and future fiscal years, reflecting continued near-term losses as the company advances its development programs. The firm expects losses of $3.41 per share in fiscal 2026 and $3.30 per share in fiscal 2027, followed by a smaller $0.56-per-share loss in fiscal 2028.
- Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to a loss of $3.41 from $2.98, and cut its fiscal 2027 forecast to a loss of $3.30 from $2.41. It also lowered estimates for third-quarter 2026, fourth-quarter 2026, fiscal 2028 and fiscal 2029, indicating expectations for greater near-term cash burn and a slower path to profitability.
- Negative Sentiment: Chief Executive Officer Berndt Modig sold 2,292 PHVS shares for approximately $79,693 at an average price of $34.77. He retained 130,625 shares, so the transaction was relatively small, but insider selling can weigh modestly on investor sentiment. SEC insider ownership filing
Institutional Investors Weigh In On Pharvaris
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Pharvaris in the fourth quarter worth about $35,000. Quantbot Technologies LP purchased a new stake in shares of Pharvaris in the second quarter worth approximately $41,000. JPMorgan Chase & Co. lifted its stake in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Barclays PLC purchased a new position in Pharvaris during the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Pharvaris during the 4th quarter valued at $86,000.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
